Home / Business and Economy / Ark Invest Swaps Meta for Google in AI Play
Ark Invest Swaps Meta for Google in AI Play
15 Sep
Summary
- Ark Invest bought Meta Platforms and sold Alphabet stock.
- The firm also increased stakes in gene-editing biotech firms.
- The trading activity suggests a more selective approach to AI.
Last week, Ark Invest, led by Cathie Wood, executed a notable rotation across its technology and biotechnology holdings. The firm made a substantial purchase of Meta Platforms, acquiring approximately 43,000 shares valued at roughly $28 million. This acquisition was balanced by the sale of nearly an equivalent amount of Alphabet shares, with approximately 86,000 shares divested for $28.6 million.
This strategic shift highlights Ark's increasingly selective approach to artificial intelligence investments, even as the firm expands its focus on speculative gene-editing companies. Beyond the Meta-Alphabet trade, Ark invested around $6.5 million in AI-chip developer Cerebras Systems, while trimming its positions in Advanced Micro Devices and Palantir Technologies. The firm also significantly increased its holdings in key biotechnology firms, adding substantial shares of Beam Therapeutics, CRISPR Therapeutics, and Intellia Therapeutics, signaling a strong conviction in the gene-editing space.
Further diversification saw Ark adding Archer Aviation, Rocket Lab, and Robinhood Markets to its portfolio, while reducing exposure to Tempus AI, Twist Bioscience, and 10x Genomics. Investors are advised to monitor the sustained pattern of Ark's trades for insights into Wood's risk-reward assessments, rather than focusing on individual transactions.
